ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0589

Distinguishing Severe Alport Syndrome from Primary FSGS Using Retinal Optical Coherence Tomography (OCT): Diagnostic Role for Temporal Thinning

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases

Authors

  • Ibrahim, Abdelrahman, University of Utah Health, Salt Lake City, Utah, United States
  • Mekki, Ossama, University of Utah Health, Salt Lake City, Utah, United States
  • Nwaduru, Chinedu Elvis, University of Utah Health, Salt Lake City, Utah, United States
  • Revelo Penafiel, Monica Patricia, University of Utah Health, Salt Lake City, Utah, United States
  • Al-Rabadi, Laith, University of Utah Health, Salt Lake City, Utah, United States
Background

Focal segmental glomerulosclerosis (FSGS) may arise from both primary immune-mediated processes and inherited disorders such as Alport syndrome (AS), complicating diagnosis and treatment. Distinguishing these entities is critical to avoid misdiagnosis and inappropriate immunosuppression. We investigated whether the Temporal Thinning Index (TTIMax), derived from retinal OCT, could differentiate primary FSGS from genetically confirmed severe AS (XLAS-M + Compound).

Methods

We compared TTIMax values in 15 patients with biopsy-confirmed primary FSGS (all receiving immunosuppressive therapy) and 43 patients with genetically confirmed male X linked AS and both male and female autosomal recessive AS.. TTIMax was calculated from OCT scans using standard ETDRS grid-based segmentation. A generalized linear model adjusted for age and sex. Renal biopsy electron microscopy was also evaluated to assess basement membrane morphology in both groups.

Results

Adjusted mean TTIMax was significantly higher in the severe AS group (11.78 ± 1.16%) than in the primary FSGS group (6.27 ± 1.06%, p < 0.001). OCT in primary FSGS showed minimal temporal thinning, while severe AS cases consistently demonstrated marked temporal macular thinning. Electron microscopy confirmed diffuse podocyte effacement in primary FSGS, compared to basement membrane lamellation, thinning, and thickening in AS-associated inherited FSGS.

Conclusion

TTIMax is a reliable noninvasive biomarker that distinguishes inherited AS-associated FSGS from primary FSGS. Integration of OCT into nephrology workups may help clarify ambiguous diagnoses, particularly when histologic and genetic findings overlap. This approach supports more accurate treatment decisions and avoidance of unnecessary immunosuppression in inherited cases.

Digital Object Identifier (DOI)